Kenya Kobayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenya Kobayashi has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Seiichi Yoshimoto
The Japan Society for Head and Neck Cancer Tokyo Japan
10 shared publicationsTatsuya Yamasoba
Departments of Otolaryngology, Head and Neck Surgery University of Tokyo Tokyo Japan
9 shared publications- Fumihiko Matsumoto
Department of Otorhinolaryngology, Juntendo University Faculty of Medicine, Tokyo, Japan
8 shared publications Satoko Matsumura
8 shared publicationsGo Omura
Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan
7 shared publications- Go Omura
Department of Head and Neck Surgery National Cancer Center Hospital Tokyo Japan
7 shared publications
Latest Publications
- Open Access
- 27 January 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (7) , 2403-2410
Histological Type‐Specific Behavior in Sarcomas: Analysis of Head and Neck Cancer Registry of Japan
Objective: The goal of this study was to better understand the epidemiology, clinical characteristics, and treatment outcomes of head and neck sarcomas using real‐world data from Japan. Methods: Using the Japanese Head and Neck Cancer Registry, we identified 438 patients who were pathologically diagnosed with head and neck sarcoma between 2011 and 2020. We compared epidemiological, clinical, and prognostic data for the different histological types of sarcoma. Results: The top five most common histopathological types were rhabdomyosarcoma, osteosarcoma, chondrosarcoma, leiomyosarcoma, and liposarcoma. The most common primary sites were the nasal cavity and paranasal sinuses. The overall cohort had clinical, pathologic, and occult lymph node positivity rate (OLR) of 18%, 15%, and 2%, respectively. Clinical lymph node positivity was highest in rhabdomyosarcoma (46%), followed by angiosarcoma (26%), with leiomyosarcoma, chondrosarcoma, and liposarcoma accounting for less than 10%. The 3‐year overall survival rate was 74.8% among the 147 patients with available prognostic information. The histological type with the lowest 3‐year overall survival was undifferentiated pleomorphic sarcoma (54%), followed by leiomyosarcoma (65%), and angiosarcoma (69%). In six of seven histological types, the 3‐year locoregional‐free survival rate was less than 70%. Conclusion: Sarcomas of the head and neck most commonly occur in the nasal cavity and paranasal sinuses. The prevalent histological type depended on the primary site. Rhabdomyosarcoma and angiosarcoma are histological types with a high risk of cervical metastasis. In the head and neck region, there are numerous histological types many of which lack local control. Level of Evidence: 3 Laryngoscope , 135:2403–2410, 2025
- 27 January 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (7) , 2403-2410
Open AccessHistological Type‐Specific Behavior in Sarcomas: Analysis of Head and Neck Cancer Registry of Japan
Objective: The goal of this study was to better understand the epidemiology, clinical characteristics, and treatment outcomes of head and neck sarcomas using real‐world data from Japan. Methods: Using the Japanese Head and Neck Cancer Registry, we identified 438 patients who were pathologically diagnosed with head and neck sarcoma between 2011 and 2020. We compared epidemiological, clinical, and prognostic data for the different histological types of sarcoma. Results: The top five most common histopathological types were rhabdomyosarcoma, osteosarcoma, chondrosarcoma, leiomyosarcoma, and liposarcoma. The most common primary sites were the nasal cavity and paranasal sinuses. The overall cohort had clinical, pathologic, and occult lymph node positivity rate (OLR) of 18%, 15%, and 2%, respectively. Clinical lymph node positivity was highest in rhabdomyosarcoma (46%), followed by angiosarcoma (26%), with leiomyosarcoma, chondrosarcoma, and liposarcoma accounting for less than 10%. The 3‐year overall survival rate was 74.8% among the 147 patients with available prognostic information. The histological type with the lowest 3‐year overall survival was undifferentiated pleomorphic sarcoma (54%), followed by leiomyosarcoma (65%), and angiosarcoma (69%). In six of seven histological types, the 3‐year locoregional‐free survival rate was less than 70%. Conclusion: Sarcomas of the head and neck most commonly occur in the nasal cavity and paranasal sinuses. The prevalent histological type depended on the primary site. Rhabdomyosarcoma and angiosarcoma are histological types with a high risk of cervical metastasis. In the head and neck region, there are numerous histological types many of which lack local control. Level of Evidence: 3 Laryngoscope , 135:2403–2410, 2025
- Open Access
- 23 October 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (2) , 622-625
Meticulous Approach to Medial Palpebral Ligament in Lateral Rhinotomy: Avoiding Canthus Malposition
The positional stability of the inner canthus is mainly provided by the anterior limb of the medial palpable ligament (MPL). Proper repair of the anterior limb of the MPL is extremely important to prevent postoperative canthus malposition. This video presents proven techniques and technical tips for MPL management in medial maxillectomy via a lateral rhinotomy. Laryngoscope, 2024.
- 23 October 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (2) , 622-625
Open AccessMeticulous Approach to Medial Palpebral Ligament in Lateral Rhinotomy: Avoiding Canthus Malposition
The positional stability of the inner canthus is mainly provided by the anterior limb of the medial palpable ligament (MPL). Proper repair of the anterior limb of the MPL is extremely important to prevent postoperative canthus malposition. This video presents proven techniques and technical tips for MPL management in medial maxillectomy via a lateral rhinotomy. Laryngoscope, 2024.
- Open Access
- 8 December 2023
- Published by Wiley in Head & Neck
- Vol. 46 (2) , 367-377
Ultra‐high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma
Background: Biomarkers that predict response to immune checkpoint inhibitor (ICI) in recurrent metastatic squamous cell carcinoma of the head and neck (RMHNSCC) are not well known.Methods: We prospectively measured the combined positive score (CPS) and administered ICI to patients with RMHNSCC.Results: Of 51 patients, 23 patients had a CPS 3.5 (HR 0.3463, p = 0.01354) were the significant factors and plus chemotherapy (HR 0.4648, p = 0.07632) was not significant. Seven patients (14%) with CPS ≥90 and albumin >3.5 showed a 2‐year survival rate of 66. 7%.Conclusions: CPS ≥90 and albumin >3.5 cases are a subgroup of RMHNSCC that respond extremely well to ICI.
- 8 December 2023
- Published by Wiley in Head & Neck
- Vol. 46 (2) , 367-377
Open AccessUltra‐high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma
Background: Biomarkers that predict response to immune checkpoint inhibitor (ICI) in recurrent metastatic squamous cell carcinoma of the head and neck (RMHNSCC) are not well known.Methods: We prospectively measured the combined positive score (CPS) and administered ICI to patients with RMHNSCC.Results: Of 51 patients, 23 patients had a CPS 3.5 (HR 0.3463, p = 0.01354) were the significant factors and plus chemotherapy (HR 0.4648, p = 0.07632) was not significant. Seven patients (14%) with CPS ≥90 and albumin >3.5 showed a 2‐year survival rate of 66. 7%.Conclusions: CPS ≥90 and albumin >3.5 cases are a subgroup of RMHNSCC that respond extremely well to ICI.
- Open Access
- 10 October 2023
- Published by Wiley in Head & Neck
- Vol. 45 (12) , 3107-3118
TERT promoter mutation positive oral cavity carcinomas, a clinically and genetically distinct subgroup of head and neck squamous cell carcinomas
Backgrounds: The importance of TERT promoter (pTERT) mutation of oral cavity squamous cell carcinoma (OCSCC) with clinical features and genetic alterations are not well recognized.Methods: We retrospectively analyzed genetic data from multiple databases, including 260 cases from the C-CAT database, 407 cases from the MSK-MetTropism database, and 40 OCSCC datasets from in-house clinical samples.Results: From C-CAT database, TP53 (66%), CDKN2A (51%), and pTERT (29%) were the most frequent mutations observed. pTERT mutations were more prevalent in OCSCC (63%), younger individuals, and women (46%), with lower rates of alcohol abuse and smoking and co-mutated with TP53, HRAS, and CASP8. MSK-MetTroposim data validated with the enrichment of pTERT mutations in OCSCC, among women and Asian individuals. In-house datasets OCSCC with pTERT mutation (50%) characterized by fewer recurrent neck metastases.Conclusion: The study suggests that OCSCC with pTERT mutation represents a distinct subgroup with unique clinical and genetic characteristics.
- 10 October 2023
- Published by Wiley in Head & Neck
- Vol. 45 (12) , 3107-3118
Open AccessTERT promoter mutation positive oral cavity carcinomas, a clinically and genetically distinct subgroup of head and neck squamous cell carcinomas
Backgrounds: The importance of TERT promoter (pTERT) mutation of oral cavity squamous cell carcinoma (OCSCC) with clinical features and genetic alterations are not well recognized.Methods: We retrospectively analyzed genetic data from multiple databases, including 260 cases from the C-CAT database, 407 cases from the MSK-MetTropism database, and 40 OCSCC datasets from in-house clinical samples.Results: From C-CAT database, TP53 (66%), CDKN2A (51%), and pTERT (29%) were the most frequent mutations observed. pTERT mutations were more prevalent in OCSCC (63%), younger individuals, and women (46%), with lower rates of alcohol abuse and smoking and co-mutated with TP53, HRAS, and CASP8. MSK-MetTroposim data validated with the enrichment of pTERT mutations in OCSCC, among women and Asian individuals. In-house datasets OCSCC with pTERT mutation (50%) characterized by fewer recurrent neck metastases.Conclusion: The study suggests that OCSCC with pTERT mutation represents a distinct subgroup with unique clinical and genetic characteristics.
- 30 September 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (11) , 1092-1093
Survival analysis of high-grade salivary gland carcinoma adjusted for length bias due to delay in comprehensive genomic profiling
We appreciate your interest in our database study, as well as your thoughtful and constructive suggestions. The 3- and 5-year overall survival rates in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort were 77 and 69% for salivary duct carcinoma (SDC) and 90 and 88% for adenoid cystic carcinoma (ACC), respectively. In several previous studies, the 3- and 5-year overall survival rates for SDC were 78–70 and 64–32%, respectively ( 1–6). On the other hand, ACC is a unique tumor with slow and persistent progression, which known to have a distinctive course with 5-year survival rates of 87–70%, 10-year survival rates of 67–54% and 15-year survival rates of 49–37% ( 7–9). Therefore, the present cohort is not a population with a favorable prognostic bias. However, due to the median follow-up of 31 months, long-term prognostic data are unreliable. Additionally, as pointed out by Ikegami et al., real-world datasets combining clinical and genomic data may be affected by left truncation (i.e. the phenomenon in which potential study participants are excluded because they have already passed the ‘milestone of interest’ at the time of study recruitment), and the resulting bias, termed length bias, affects survival outcomes ( 10). Therefore, we also evaluated the association between left truncation time (time from diagnosis to comprehensive genomic profiling (CGP)) and overall survival using the conditional Kendall tau statistic (Tc) ( 11). This statistic had a positive value for both ACC and SDC (ACC: conditional Kendall tau = 0.134, SE = 0.089, Z = 1.498, P = 0.134; SDC: conditional Kendall tau = 0.413, SE = 0.190, Z = 2.171, P = 0.029). The positive values indicate that left truncation time and survival time were not quasi-independent, and shorter overall survival was associated with a shorter time to CGP testing ( 11). These results are consistent with previous C-CAT data reported by Ikegami et al.
- 30 September 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (11) , 1092-1093
Survival analysis of high-grade salivary gland carcinoma adjusted for length bias due to delay in comprehensive genomic profiling
We appreciate your interest in our database study, as well as your thoughtful and constructive suggestions. The 3- and 5-year overall survival rates in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort were 77 and 69% for salivary duct carcinoma (SDC) and 90 and 88% for adenoid cystic carcinoma (ACC), respectively. In several previous studies, the 3- and 5-year overall survival rates for SDC were 78–70 and 64–32%, respectively ( 1–6). On the other hand, ACC is a unique tumor with slow and persistent progression, which known to have a distinctive course with 5-year survival rates of 87–70%, 10-year survival rates of 67–54% and 15-year survival rates of 49–37% ( 7–9). Therefore, the present cohort is not a population with a favorable prognostic bias. However, due to the median follow-up of 31 months, long-term prognostic data are unreliable. Additionally, as pointed out by Ikegami et al., real-world datasets combining clinical and genomic data may be affected by left truncation (i.e. the phenomenon in which potential study participants are excluded because they have already passed the ‘milestone of interest’ at the time of study recruitment), and the resulting bias, termed length bias, affects survival outcomes ( 10). Therefore, we also evaluated the association between left truncation time (time from diagnosis to comprehensive genomic profiling (CGP)) and overall survival using the conditional Kendall tau statistic (Tc) ( 11). This statistic had a positive value for both ACC and SDC (ACC: conditional Kendall tau = 0.134, SE = 0.089, Z = 1.498, P = 0.134; SDC: conditional Kendall tau = 0.413, SE = 0.190, Z = 2.171, P = 0.029). The positive values indicate that left truncation time and survival time were not quasi-independent, and shorter overall survival was associated with a shorter time to CGP testing ( 11). These results are consistent with previous C-CAT data reported by Ikegami et al.
- 7 August 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (11) , 1045-1050
Clinical outcomes of head and neck mucosal melanoma treated with surgery: a single-center study in Japan
Head and neck mucosal melanomas are rare malignancies. Although the prognosis is poor owing to the high incidence of distant metastases, locoregional control remains important. It is difficult to obtain results in a large cohort because of its rarity. This study aimed to elucidate the survival outcomes of patients with head and neck mucosal melanoma treated with surgery in Japan. Patients with head and neck mucosal melanoma who were surgically treated between 2007 and 2021 at the National Cancer Center Hospital were retrospectively analyzed. A total of 47 patients were included in this study. The 5-year overall survival, disease-specific survival, locoregional control and relapse-free survival rates were 42%, 50%, 79% and 13%, respectively. The disease-specific survival of the oral mucosal melanoma group was significantly better than that of the sinonasal mucosal melanoma group (5-year disease-specific survival rate: 70% versus 37%, respectively; P = 0.04). Multivariate analyses revealed that sinonasal mucosal melanoma were independently significant adverse prognostic factor, for overall survival and disease-specific survival. Patients with oral mucosal melanoma patients had a higher incidence of lymph node metastasis than those with sinonasal mucosal melanoma patients (P < 0.0001). This study demonstrated the survival outcomes of the largest cohort of patients with head and neck mucosal melanomas treated surgically at a single institution within the past 20 years in Japan. We found that survival outcomes and incidence of nodal metastases varied by site.
- 7 August 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (11) , 1045-1050
Clinical outcomes of head and neck mucosal melanoma treated with surgery: a single-center study in Japan
Head and neck mucosal melanomas are rare malignancies. Although the prognosis is poor owing to the high incidence of distant metastases, locoregional control remains important. It is difficult to obtain results in a large cohort because of its rarity. This study aimed to elucidate the survival outcomes of patients with head and neck mucosal melanoma treated with surgery in Japan. Patients with head and neck mucosal melanoma who were surgically treated between 2007 and 2021 at the National Cancer Center Hospital were retrospectively analyzed. A total of 47 patients were included in this study. The 5-year overall survival, disease-specific survival, locoregional control and relapse-free survival rates were 42%, 50%, 79% and 13%, respectively. The disease-specific survival of the oral mucosal melanoma group was significantly better than that of the sinonasal mucosal melanoma group (5-year disease-specific survival rate: 70% versus 37%, respectively; P = 0.04). Multivariate analyses revealed that sinonasal mucosal melanoma were independently significant adverse prognostic factor, for overall survival and disease-specific survival. Patients with oral mucosal melanoma patients had a higher incidence of lymph node metastasis than those with sinonasal mucosal melanoma patients (P < 0.0001). This study demonstrated the survival outcomes of the largest cohort of patients with head and neck mucosal melanomas treated surgically at a single institution within the past 20 years in Japan. We found that survival outcomes and incidence of nodal metastases varied by site.
- Open Access
- 28 June 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (1) , 228-235
Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer
Objective: Immune checkpoint inhibitors (ICI) have become widely used becuse of their effectiveness and relatively low rate of severe adverse events. However, active treatment should be continued after discontinuation of ICI as response rates are lower than that of conventional cytotoxic chemotherapy. The purpose of the present study was to determine the efficacy of treatment after ICI discontinuation.Methods: This was a retrospective study from hospital charts of 99 consecutive cases treated with ICI at our facility since 2017. Of these, 79 cases of squamous cell carcinoma which had already discontinued ICI were enrolled in the present study.Results: After discontinuation of ICI, 40 cases received active treatment with salvage chemotherapy (SCTx; 33 cases) or surgery or radiotherapy (seven patients) and 39 cases received nonactive treatment. SCTx comprising paclitaxel and cetuximab (PTX‐Cmab) was administered to 15 cases and other SCTx regimens to 18 cases. A significant increase in overall survival (OS) was observed with active treatment compared with nonactive treatment. No significant differences in OS or progression‐free survival (PFS) were observed between SCTx regimens; however, there was a trend toward increased survival with PTX‐Cmab. Univariate analysis of overall response rate (ORR) demonstrated significant differences in the site of disease at ICI and SCTx regimens. A significant difference in disease control rate was observed between SCTx regimens. Multivariate analysis of ORR demonstrated a significant correlation with PTX‐Cmab treatment.Conclusion: Active treatment after ICI discontinuation and the use of PTX‐Cmab as SCTx may increase OS in head and neck squamous cell carcinoma.Level of Evidence: 4 Laryngoscope, 134:228–235, 2024
- 28 June 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (1) , 228-235
Open AccessEfficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer
Objective: Immune checkpoint inhibitors (ICI) have become widely used becuse of their effectiveness and relatively low rate of severe adverse events. However, active treatment should be continued after discontinuation of ICI as response rates are lower than that of conventional cytotoxic chemotherapy. The purpose of the present study was to determine the efficacy of treatment after ICI discontinuation.Methods: This was a retrospective study from hospital charts of 99 consecutive cases treated with ICI at our facility since 2017. Of these, 79 cases of squamous cell carcinoma which had already discontinued ICI were enrolled in the present study.Results: After discontinuation of ICI, 40 cases received active treatment with salvage chemotherapy (SCTx; 33 cases) or surgery or radiotherapy (seven patients) and 39 cases received nonactive treatment. SCTx comprising paclitaxel and cetuximab (PTX‐Cmab) was administered to 15 cases and other SCTx regimens to 18 cases. A significant increase in overall survival (OS) was observed with active treatment compared with nonactive treatment. No significant differences in OS or progression‐free survival (PFS) were observed between SCTx regimens; however, there was a trend toward increased survival with PTX‐Cmab. Univariate analysis of overall response rate (ORR) demonstrated significant differences in the site of disease at ICI and SCTx regimens. A significant difference in disease control rate was observed between SCTx regimens. Multivariate analysis of ORR demonstrated a significant correlation with PTX‐Cmab treatment.Conclusion: Active treatment after ICI discontinuation and the use of PTX‐Cmab as SCTx may increase OS in head and neck squamous cell carcinoma.Level of Evidence: 4 Laryngoscope, 134:228–235, 2024
- 24 June 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (9) , 798-807
CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database
Due to the diversity of histopathologic types in salivary gland carcinoma, genomic analysis of large cohorts with next-generation sequencing by histologic type has not been adequately performed. We analysed data from 93 patients with salivary duct carcinoma and 243 patients with adenoid cystic carcinoma who underwent comprehensive genomic profiling testing in the Center for Cancer Genomics and Advanced Therapeutics database, a Japanese national genome profiling database. We visualised gene mutation profiles using the OncoPrinter platform. Fisher’s exact test, Kaplan–Meier analysis, log-rank test and Cox regression models were used for statistical analysis. In salivary duct carcinoma, a population with CDK12 and ERBB2 co-amplification was detected in 20 of 37 (54.1%) patients with ERBB2 amplification. We identified five loss-of-function variants in genes related to homologous recombination deficiency, such as BRCA2 and CDK12. Cox survival analysis showed that CDK12 and ERBB2 co-amplification is associated with overall survival (hazard ratio, 3.597; P = 0.045). In salivary duct carcinoma, NOTCH1 mutations were the most common, followed by mutations in chromatin modification genes such as KMT2D, BCOR, KDM6A, ARID1A, EP300 and CREBBP. In the multivariate Cox analysis, activating NOTCH1 mutations (hazard ratio, 3.569; P = 0.009) and ARID1A mutations (hazard ratio, 4.029; P = 0.034) were significantly associated with overall survival. CDK12 and ERBB2 co-amplification is associated with a poor prognosis in salivary duct carcinoma. Chromatin remodelling genes are deeply involved in tumour progression in adenoid cystic carcinoma. One such gene, ARID1A, was an independent prognostic factor. In salivary duct carcinoma and adenoid cystic carcinoma, there might be minor populations with mutations that could be targeted for treatment with the synthetic lethality approach.
- 24 June 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (9) , 798-807
CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database
Due to the diversity of histopathologic types in salivary gland carcinoma, genomic analysis of large cohorts with next-generation sequencing by histologic type has not been adequately performed. We analysed data from 93 patients with salivary duct carcinoma and 243 patients with adenoid cystic carcinoma who underwent comprehensive genomic profiling testing in the Center for Cancer Genomics and Advanced Therapeutics database, a Japanese national genome profiling database. We visualised gene mutation profiles using the OncoPrinter platform. Fisher’s exact test, Kaplan–Meier analysis, log-rank test and Cox regression models were used for statistical analysis. In salivary duct carcinoma, a population with CDK12 and ERBB2 co-amplification was detected in 20 of 37 (54.1%) patients with ERBB2 amplification. We identified five loss-of-function variants in genes related to homologous recombination deficiency, such as BRCA2 and CDK12. Cox survival analysis showed that CDK12 and ERBB2 co-amplification is associated with overall survival (hazard ratio, 3.597; P = 0.045). In salivary duct carcinoma, NOTCH1 mutations were the most common, followed by mutations in chromatin modification genes such as KMT2D, BCOR, KDM6A, ARID1A, EP300 and CREBBP. In the multivariate Cox analysis, activating NOTCH1 mutations (hazard ratio, 3.569; P = 0.009) and ARID1A mutations (hazard ratio, 4.029; P = 0.034) were significantly associated with overall survival. CDK12 and ERBB2 co-amplification is associated with a poor prognosis in salivary duct carcinoma. Chromatin remodelling genes are deeply involved in tumour progression in adenoid cystic carcinoma. One such gene, ARID1A, was an independent prognostic factor. In salivary duct carcinoma and adenoid cystic carcinoma, there might be minor populations with mutations that could be targeted for treatment with the synthetic lethality approach.
- Open Access
- 10 June 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (9) , 743-756
Current topics and management of head and neck sarcomas
Given the low incidence, variety of histological types, and heterogeneous biological features of head and neck sarcomas, there is limited high-quality evidence available to head and neck oncologists. For resectable sarcomas, surgical resection followed by radiotherapy is the principle of local treatment, and perioperative chemotherapy is considered for chemotherapy-sensitive sarcomas. They often originate in anatomical border areas such as the skull base and mediastinum, and they require a multidisciplinary treatment approach considering functional and cosmetic impairment. Moreover, head and neck sarcomas may exhibit different behaviour and characteristics than sarcomas of other areas. In recent years, the molecular biological features of sarcomas have been used for the pathological diagnosis and development of novel agents. This review describes the historical background and recent topics that head and neck oncologists should know about this rare tumour from the following five perspectives: (i) epidemiology and general characteristics of head and neck sarcomas; (ii) changes in histopathological diagnosis in the genomic era; (iii) current standard treatment by histological type and clinical questions specific to head and neck; (iv) new drugs for advanced and metastatic soft tissue sarcomas; and (v) proton and carbon ion radiotherapy for head and neck sarcomas.
- 10 June 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (9) , 743-756
Open AccessCurrent topics and management of head and neck sarcomas
Given the low incidence, variety of histological types, and heterogeneous biological features of head and neck sarcomas, there is limited high-quality evidence available to head and neck oncologists. For resectable sarcomas, surgical resection followed by radiotherapy is the principle of local treatment, and perioperative chemotherapy is considered for chemotherapy-sensitive sarcomas. They often originate in anatomical border areas such as the skull base and mediastinum, and they require a multidisciplinary treatment approach considering functional and cosmetic impairment. Moreover, head and neck sarcomas may exhibit different behaviour and characteristics than sarcomas of other areas. In recent years, the molecular biological features of sarcomas have been used for the pathological diagnosis and development of novel agents. This review describes the historical background and recent topics that head and neck oncologists should know about this rare tumour from the following five perspectives: (i) epidemiology and general characteristics of head and neck sarcomas; (ii) changes in histopathological diagnosis in the genomic era; (iii) current standard treatment by histological type and clinical questions specific to head and neck; (iv) new drugs for advanced and metastatic soft tissue sarcomas; and (v) proton and carbon ion radiotherapy for head and neck sarcomas.